CHMP recommendation for Nuwiq for treatment of Haemophilia - Octapharma AG
Octapharma confirmed that the European Medicines Agency (EMA) has adopted a positive opinion towards human cell line recombinant human FVIII, Nuwiq, recommending the granting of a marketing authorisation for the medicinal product for treatment and prophylaxis of bleeding (also during and after surgery) in paediatric and adult patients with Haemophilia A.
Nuwiq is the first new generation FVIII replacement protein, derived from a human cell line awaiting marketing authorisation in Europe. Nuwiq is produced without animal derived products, and devoid of non human epitopes thought to underlie autoimmune reaction. Inhibitor antibodies to replacement FVIII typically neutralise the beneficial effect of the protein, and represent the major challenge in today's management of Haemophilia.
Related news and insights
Santen Pharmaceutical has obtained Chinese regulatory approval for Verkazia (ciclosporin) eye drops for the treatment of severe vernal keratoconjunctivitis (VKC) in children and adolescents aged four years and older.
Mitsubishi Tanabe Pharma Corporation announced that the FDA has approved Radicava ORS (edaravone) for the treatment of amyotrophic lateral sclerosis (ALS) on May 12, 2022. Radicava ORS is an oral suspension formulation that contains the same active ingredient as edaravone for intravenous infusion (Japanese product name: Radicut Injection 30 mg and Radicut Bag for I.V. Infusion 30 mg) for ALS treatment and being developed globally, primarily by Mitsubishi Tanabe Pharma Development America, Inc.
The National Institute for Health and Care Excellence recommends selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over.